Expert Interview
Discussing the potential of Zuranolone (SAGE-217) in Major Depressive Disorder before NDA expected in the 2nd Half of 2022
Ticker(s): SAGEInstitution: UC Irvine
- Assistant Professor of Psychiatry” at UC Irvine Medical Center.
- Currently manages ~60 patients with bipolar depression.
- Familiar with the published literature for lumateperone in treating bipolar depression.
- Manages 100 patients with MDD
- Familiar with the published literature for AXS-05 in treating major depressive disorder.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
